Panax ginseng enhances the effect of metoprolol in chronic heart failure by inhibiting autophagy
Niu Zi‐Chang, Han Xiaoling, Liu Ting, Jin Qi, Ouyang Ming-Hui, Haoping MaoiD
Abstract
ContextPanax ginseng is often used as an adjuvant therapy for heart failure (HF) patients. Metoprolol is widely used in patients with HF. However, there is currently no report on the combined effects of ginseng and metoprolol in patients with HF. ObjectiveThe objective of this study is to investigate the combined effects of ginseng and metoprolol in patients with HF and the exact mechanisms. Materials and methodsA mouse myocardial HF model was used. The serum levels of CK and CK-MB were determined using an automated biochemical analyzer. LDH and cTnT levels were determined using enzyme-linked immunosorbent assays. Autophagy of myocardial cells was evaluated using transmission electron microscopy, and changes in signal pathway proteins related to autophagy were analyzed using Western blot. ResultsThe combination of ginseng and metoprolol can increase the survival rate of HF mice, improve heart function, reduce heart damage, and reduce serum CK, CK-MB, LDH, and cTnT levels. The combination of ginseng and metoprolol reduces autophagy in myocardial cells, reduces the levels of autophagy-related proteins (LC3, p62, Beclin1, and Atg5), and increases the p-PI3K/PI3K, p-Akt/Akt, and p-mTOR/mTOR ratios. Discussion and conclusionGinseng enhances the anti-HF effect of metoprolol. Its mechanism of action may be related to inhibition of autophagy mediated by the PI3K/Akt/mTOR pathway.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 1.66
- Field percentile
- top 21%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of Cardiac p38 Highlights the Role of the Phosphoproteome in Heart Failure Progression
Sogol Sedighi, Ting Liu, … D. Brian Foster·ACS OmegaPeer-reviewed·Aug 6, 2025
- Efficacy of a Growth Hormone-Releasing Hormone Agonist in a Murine Model of Cardiometabolic Heart Failure with Preserved Ejection Fraction
R. M. K. Takeuchi, L. M. Takeuchi, … J. M. Hare·bioRxiv·Sep 18, 2022
- Synthetic Agonist of Growth Hormone-Releasing Hormone as Novel Treatment for Heart Failure with Preserved Ejection Fraction
R. A. Dulce, R. M. Kanashiro-Takeuchi, … J. M. Hare·bioRxiv·Feb 28, 2020
- Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation And Cardiac Remodeling
Rajesh Chaudhary, Andrew Robbins, … Ahmed Abdel‐Latif·bioRxiv·Aug 30, 2026
- Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of Growth Hormone-Releasing Hormone (GHRH)
Rosemeire M. Kanashiro‐Takeuchi, Lauro Mitsuru Takeuchi, … Joshua M. Hare·American Journal of Physiology-Heart and Circulatory PhysiologyPeer-reviewed·Aug 1, 2026
- Pannexin 1 Channels Control Cardiomyocyte Metabolism and Neutrophil Recruitment During Non-Ischemic Heart Failure
C. M. Pavelec, A. Young, … N. Leitinger·bioRxiv·Dec 29, 2023